Trifluperidol

Summary

Trifluperidol (CHEMBL15023) is an approved small molecule (ATC N05AD02); indicated across 1 condition including psychotic disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AD02
• Indications: 1 condition
• Chemistry: 409.4 Da · C22H23F4NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL15023
Name	Trifluperidol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5567
ATC	N05AD02
Molecular formula	C22H23F4NO2
Molecular weight	409.4
InChIKey	GPMXUUPHFNMNDH-UHFFFAOYSA-N

SMILES: C1CN(CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F

IUPAC name: 1-(4-fluorophenyl)-4-[4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]butan-1-one

Also known as: MCN-JR-2498, NSC-170978, R-2498, Trifluperidol, trifluperidol, SID11111838, SID90340861, SID50111276, TRIFLUPERIDOL

Parent form; salt/anhydrous children: CHEMBL1257039

Patent coverage: 697 distinct patent families (2,646 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,644 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Pyruvate kinase PKM, Thrombopoietin, Thyrotropin receptor, Muscarinic acetylcholine receptor M1, Serine/threonine-protein kinase mTOR, Sigma non-opioid intracellular receptor 1, Cytochrome P450 2D6, C-8 sterol isomerase ERG2, Cytochrome P450 3A4, Sigma non-opioid intracellular receptor 1.

Bioactivity

ChEMBL activities: 13 potent at pChembl ≥ 5 of 23 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P32352	9.82	Ki	0.15	nM	CHEMBL_ACT_1483990
Q9R0C9	9.1	Ki	0.8	nM	CHEMBL_ACT_2691183
SIGMAR1	9.08	Ki	0.83	nM	CHEMBL_ACT_1483989
MAPK1	8.4	Potency	4	nM	CHEMBL_ACT_4533836
PKM	8.3	Potency	5	nM	CHEMBL_ACT_4388251
PKM	8.3	Potency	5	nM	CHEMBL_ACT_4583914
CYP3A4	7.4	Potency	39.8	nM	CHEMBL_ACT_5002111
CYP3A4	7.4	Potency	39.8	nM	CHEMBL_ACT_5070725
CYP3A4	7.4	AC50	39.81	nM	CHEMBL_ACT_6057388
EBP	6.78	Ki	165	nM	CHEMBL_ACT_1483988
CYP2D6	6.77	Ki	170	nM	CHEMBL_ACT_416613
CYP2D6	6.3	Potency	501.2	nM	CHEMBL_ACT_5006549
CYP2D6	6.3	AC50	501.2	nM	CHEMBL_ACT_5987030

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).